Vistagen Therapeutics (VTGN) Current Deferred Revenue (2011 - 2026)
Vistagen Therapeutics' Current Deferred Revenue was $96,000 in fiscal Q2 2027 (quarter ended Sep 30, 2026), down 95.5% from $2.14 million a year earlier and down 59.0% from the prior quarter.
Vistagen Therapeutics (VTGN) Current Deferred Revenue (2011 - 2026) Analysis & Trends
At the end of FY2026 (ended Mar 31, 2026), Current Deferred Revenue at Vistagen Therapeutics came in at $1.71 million, down 33.9% from FY2025.
- Current Deferred Revenue shows a five-year compound annual growth rate of 3.8% (FY2021 to FY2026).
- In earlier fiscal years, Current Deferred Revenue was $2.59 million in FY2025 (+227.2%), $791,000 in FY2024 (+10.8%), $714,000 in FY2023 (-42.6%) and $1.24 million in FY2022 (-12.4%).
- The fiscal Q2 2027 figure marks the lowest quarterly Current Deferred Revenue since fiscal Q4 2012.
- Compared with a year earlier, Current Deferred Revenue has declined for five straight quarters, with growth averaging 3.2% over the last eight quarters.
- The best year-over-year quarter for Current Deferred Revenue over five years was fiscal Q4 2025 (growth of 227.2%); the worst was fiscal Q2 2027 (a decline of 95.5%).
- Per Business Quant data, VTGN's Current Deferred Revenue in the three fiscal quarters before Q2 2027 was $234,000 (Q1 2027), $1.71 million (Q4 2026) and $2 million (Q3 2026).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | PetVivo Holdings | 3,096.39 Bn | 3,096.39 Bn | 196,075.00 |
| 2 | Eli Lilly | 1,202.70 Bn | 1,176.32 Bn | 20.46 Bn |
| 3 | Johnson & Johnson | 649.77 Bn | 569.63 Bn | 17.30 Bn |
| 4 | AbbVie | 507.00 Bn | 475.00 Bn | 13.12 Bn |
| 5 | Merck | 329.70 Bn | 292.64 Bn | 13.19 Bn |
| 6 | Novartis Ag | 291.91 Bn | 265.14 Bn | - |
| 7 | Amgen | 236.26 Bn | 187.91 Bn | 7.58 Bn |
| 8 | Gilead Sciences | 207.15 Bn | 182.26 Bn | 6.73 Bn |
| 9 | Gsk | 193.54 Bn | 176.38 Bn | - |
| 10 | Vistagen Therapeutics | 7.34 Mn | -151.60 Mn | - |
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | 96,000.00 |
| Jun 30, 2026 | 234,000.00 |
| Mar 31, 2026 | 1.71 Mn |
| Dec 31, 2025 | 2.00 Mn |
| Sep 30, 2025 | 2.14 Mn |
| Jun 30, 2025 | 2.51 Mn |
| Mar 31, 2025 | 2.59 Mn |
| Dec 31, 2024 | 2.51 Mn |
| Sep 30, 2024 | 2.47 Mn |
| Jun 30, 2024 | 2.30 Mn |
| Mar 31, 2024 | 791,000.00 |
| Dec 31, 2023 | 1.76 Mn |
| Sep 30, 2023 | 793,000.00 |
| Jun 30, 2023 | 714,300.00 |
| Mar 31, 2023 | 714,000.00 |
| Dec 31, 2022 | 712,300.00 |
| Sep 30, 2022 | 712,300.00 |
| Jun 30, 2022 | 1.24 Mn |
| Mar 31, 2022 | 1.24 Mn |
| Dec 31, 2021 | 1.42 Mn |
Vistagen Therapeutics Current Deferred Revenue API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=VTGN&period=max&api_key=YOUR_API_KEY
import requests
url = "https://data.businessquant.com/historic"
params = {"slug": "current-deferred-revenue", "ticker": "VTGN", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()
const res = await fetch("https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=VTGN&period=max&api_key=YOUR_API_KEY");
const data = await res.json();